Final Guidance From FDA Recommends Study Approach For Glycemic Control Devices
Executive Summary
The document explains how the US agency wants researchers to conduct early-stage studies of the devices, which attempt to control blood sugar through bariatric, neurostimulation, and other treatments.
You may also be interested in...
New Draft Guidance From US FDA Discusses Trials For Novel Diabetes Treatments
The document discusses feasibility studies on devices that use therapies like neurostimulation or changes to the small intestine to better control blood glucose levels in people with type 2 diabetes.
EPA Gives Stakeholders Additional 15 Days For EtO Comments
The deadline for comments on the Environmental Protection Agency proposal, which trade groups say could lead to device shortages if implemented, has been moved from 12 June to 27 June.
‘Wait-and-See Time’: Panel Predicts Limited Congressional Action On Devices This Year
An expert panel at the FDLI annual meeting expects the US Congress to want to see more results from recent legislation on devices before it moves ahead with further FDA reform. Though, pandemic-related measures remain a priority.